secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0000950170-22-007369
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion reports Q1 net loss $13.0M; CY6463 MELAS data expected Q2 2022
------------------------------------------------------------------------

- Net loss of $13.0M in Q1 2022 vs $13.4M in Q1 2021; cash balance $41M (down from $54M).
- R&D expenses rose to $9.7M from $8.0M due to external research costs; G&A fell to $4.0M from $5.4M.
- MELAS study enrollment closed; topline data expected Q2 2022.
- CIAS study enrollment closed; topline data expected Q3 2022.
- Alzheimer's disease with vascular pathology (ADv) study enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022007369/0000950170-22-007369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022007369/cycn-20220504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer